EMA held this virtual meeting to explain the processes for the development, evaluation, approval and safety monitoring of COVID-19 vaccines in the EU, including EMA’s specific role, to all interested parties.
The meeting also gave the opportunity to the public and stakeholder groups to speak and share their needs, expectations and any concerns. This feedback will be considered by EMA and the European medicines regulatory network in the decision-making process.
Please note that some issues of high public interest, such as patient access to COVID-19 vaccines and national vaccination campaigns, lie outside EMA’s remit and were not covered at this event.
Follow this event on Twitter using the hashtag #EMAPublicMeeting.
Presentation – How are COVID-19 vaccines developed? (Marco Cavaleri) (PDF/396.11 KB) (new)
Presentation – EU’s regulatory process for evaluation and approval of vaccines (Fergus Sweeney) (PDF/296.77 KB) (new)
Presentation – Safety monitoring of COVID-19 vaccines (Peter Arlett) (PDF/377.22 KB) (new)
Presentation – Transparency, engagement and communication (Melanie Carr) (PDF/1.03 MB) (new)
First published: 11/12/2020